COVID-19 & CancerFreeGuest Editorial COVID-19 and community cancer careA Panorama of a Catastrophe May 08, 2020Vol.46 No.19By Debra Patt and Michael Kolodziej
Clinical RoundupFree Phase III trial evaluating Libtayo in NSCLC halted because of significant OS improvement May 01, 2020Vol.46 No.18
Clinical RoundupFree Lynparza demonstrates OS benefit in phase III prostate cancer trial May 01, 2020Vol.46 No.18
Clinical RoundupFree GARNET study demonstrates potential of dostarlimab to treat recurrent or advanced endometrial cancer May 01, 2020Vol.46 No.18
Clinical RoundupFree MD Anderson, Ipsen advance therapy with potential benefit for patients with lung, ovarian cancer May 01, 2020Vol.46 No.18
Clinical RoundupFree Study: Disruptions in health insurance coverage are common, and affect cancer care and survival May 01, 2020Vol.46 No.18
Clinical RoundupFree Mouse model study shows promise in treatment of medulloblastoma and ependymoma May 01, 2020Vol.46 No.18
Drugs & TargetsFree FDA approves GSK’s PARP inhibitor Zejula for first-line maintenance of advanced ovarian cancer May 01, 2020Vol.46 No.18
